The N0147 trial in 2014 examining stage III CRC patients undergoing FOLFOX +/− cetuximab showed that KRAS mutations in both codon 12 and 13 were associated with a reduction in DFS [79]. The gene discussed is KRAS; the disease is colorectal carcinoma.